Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 9:51 AM ET


Company Overview of Novo Nordisk, Inc.

Company Overview

Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.

100 College Road West

Princeton, NJ 08540

United States

Founded in 1982





Key Executives for Novo Nordisk, Inc.

Senior Vice President of Finance and Operations
Age: 48
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Age: 61
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2015.

Novo Nordisk, Inc. Key Developments

Novo Nordisk Announces the Latest Interim Data from the Guardian 2 Extension Trial

At the International Society on Thrombosis and Haemostasis 2015 Congress, Novo Nordisk announced the latest interim data from the guardian 2 extension trial, which showed that in a phase 3 trial, Zonovate, provided long-term efficacy and safety in the prophylaxis and treatment of bleeds in people with severe haemophilia A. The pivotal guardian clinical programme was one of the large and most comprehensive preregistration clinical trial programmes in haemophilia A, with more than 210 patients with severe haemophilia A treated. Interim data collected through December 31, 2013 from 451.6 patient-years on Zonovate show results consistent with previous reports: The overall estimated median annual bleeding rate achieved during the preventive regimen with Zonovate was 1.56. During the preventive regimen, 90% of all bleeding episodes were successfully treated with one or two infusions of Zonovate. Guardian 2 is a large, multinational extension trial of Zonovate in previously treated patients with haemophilia A from 19 countries who had been enrolled in the pivotal guardian™1 and guardian 3 trials. Patients received Zonovate in a prophylactic regimen and to treat breakthrough bleeds. These findings now comprise more than four years of data and more than 450 patient years. No inhibitors to factor VIII were detected and no safety issues were identified, supporting the findings from guardian 1 and 3, demonstrating no confirmed inhibitor development in 213 previously treated patients. The most common adverse reactions seen in the study were injection-site reactions, increased hepatic enzymes and fever.

Novo Nordisk Inc. Wins $532.61 Million Federal Contract

Novo Nordisk Inc. won a $532,607,180 federal contract from the U.S. Department of Veterans Affairs National Acquisition Center, Hines, Illinois, for human insulin. The contract has four option years.

Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Dr. Reddy's Laboratories Inc. United States
Arrien Pharmaceuticals, LLC United States
CIBA Vision Ophthalmics Inc. United States
Entheogen Corporation United States
Inspire Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novo Nordisk, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at